By: Adam Feuerstein | 03/12/14 - 09:57 AM EDT
The clinical hold affects the remaining eight patients in the company`s Phase 2 study in essential thrombocythemia (ET) or polycythemia vera (PV) and the remaining two patients in the company`s Phase 2 study in multiple myeloma. In addition, the company's planned Phase 2 clinical trial in myelofibrosis will likely be delayed due to the clinical hold. It is possible that other studies using imetelstat, such as ongoing investigator-sponsored trials, may also be placed on clinical hold by the FDA.
Drug development would be so much easier if people didn't have livers. Adam Feuerstein (@adamfeuerstein) March 12, 2014Update: On a conference call this morning, Geron said the FDA concerns relate primarily to reports of "persistent" low-grade elevations in liver enzymes reported by almost all imetelstat-treated patients. Regulators want Geron to submit clinical data on the reversibility of these liver toxicity signals.
10/22/14 - 11:52 AM EDT
10/22/14 - 08:39 AM EDT
10/21/14 - 09:29 AM EDT
10/20/14 - 10:56 AM EDT
10/15/14 - 04:07 PM EDT
10/22/14 - 10:11 AM EDT
10/22/14 - 09:24 AM EDT
10/22/14 - 07:11 AM EDT
10/21/14 - 11:34 AM EDT
10/21/14 - 10:23 AM EDT
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.